CDEK
← All drugs Report issue

plinabulin

Small moleculeexperimental

Plinabulin is a small molecule under development by BeyondSpring Pharmaceuticals, and has completed a world-wide Phase 3 clinical trial for non-small cell lung cancer. Plinabulin is being investigated for the reduction of chemotherapy-induced neutropenia and for anti-cancer effects in combination with immune checkpoint inhibitors and in KRAS mutated tumors. — Wikipedia

Clinical trial activity

14 trials · 15 clinical orgs · 0 marketing orgs

Phase 1
6
Phase 2
10
Phase 3
3
Phase 4
0

Earliest trial started Apr 1, 2006 (NCT00322608)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2016

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Mol. weight
336.4 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • npi2358
  • npi 2358
  • npi-2358
  • npi-2358
  • npi-2358
  • npi-2358
  • plinabulin
  • plinabulin
  • plinabulin
  • plinabulin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05745350Phase 2Nov 30, 2023Huazhong University of Science and Technology
NCT05599789Phase 2Nov 1, 2022BeyondSpring Pharmaceuticals Inc., Chinese Academy of Medical Sciences, Merck
NCT05130827Phase 2Nov 30, 2021BeyondSpring Pharmaceuticals Inc., Memorial Sloan-Kettering Cancer Center
NCT04902040Phase 1/Phase 2 (Phase 2)Apr 14, 2021University of Texas at Houston
NCT03575793Phase 1/Phase 2 (Phase 2)Sep 6, 2018Big Ten Cancer Research Consortium, Rutgers University
NCT04227990Phase 2Nov 27, 2017BeyondSpring Pharmaceuticals Inc.
NCT03294577Phase 2/Phase 3 (Phase 3)Nov 27, 2017BeyondSpring Pharmaceuticals Inc., Stanford University
NCT04345900Phase 2Apr 5, 2017BeyondSpring Pharmaceuticals Inc.
NCT03102606Phase 2/Phase 3 (Phase 3)Mar 13, 2017BeyondSpring Pharmaceuticals Inc., Chiltern International, ICON, Stanford University
NCT02846792Phase 1/Phase 2 (Phase 2)Nov 29, 2016National Cancer Institute (NCI), University of Washington
NCT02812667Phase 1Aug 1, 2016BeyondSpring Pharmaceuticals Inc., University of California, San Diego
NCT02504489Phase 3Jun 1, 2016BeyondSpring Pharmaceuticals Inc., University of California, San Diego
NCT00630110Phase 1/Phase 2 (Phase 2)Feb 1, 2008Nereus Pharmaceuticals, Inc.
NCT00322608Phase 1Apr 1, 2006Nereus Pharmaceuticals, Inc.
Showing 14 of 14 trials
Page 1 / 1

Organizations

Research & Development (15)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
BeyondSpring Pharmaceuticals Inc.For profit8532016
Nereus Pharmaceuticals, Inc.For profit2222006
Stanford UniversityAcademic/Hospital2012017
University of California, San DiegoAcademic/Hospital2122016
Big Ten Cancer Research ConsortiumAcademic/Hospital1012018
Chiltern InternationalFor profit1012017
Chinese Academy of Medical SciencesAcademic/Hospital1112022
Huazhong University of Science and TechnologyAcademic/Hospital1112023
ICONFor profit1012017
Memorial Sloan-Kettering Cancer CenterAcademic/Hospital1112021
MerckFor profit1012022
National Cancer Institute (NCI)Government1012016
Rutgers UniversityAcademic/Hospital1112018
University of Texas at HoustonAcademic/Hospital1112021
University of WashingtonAcademic/Hospital1112016
15 organizations
Page 1 / 1